triple glp-1/gip/glucagon receptor agonist New strategies for the treatment of obesity and metabolic dysfunctions LY3437943, a novel triple glucagon,

It works by triggering the release of certain neurotransmitters in the brain that can decrease appetite

References 1 MalikVSWilletWCHuFB

Many of these companies are privately held and receive far less attention than the big pharma names, yet they hold critical capacity positions in the scaleup process now underway

It is often the smarter long-term investment in your health

Aroda VR, Erhan U, Jelnes P, et al

Three of the four exenatide studies compared the odds of having pancreatitis requiring hospitalization relative to patients using other diabetes medications, and identified 1-year incidence rates from 0.132% to 0.196% versus 0.133% to 0.249% in comparison patients